These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 32866691

  • 1. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
    Sroubek J, Matos J, Locke A, Kaplinskiy V, Levine YC, Shen C, Buxton AE.
    Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
    [Abstract] [Full Text] [Related]

  • 2. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias.
    Levine YC, Rosenberg MA, Mittleman M, Samuel M, Methachittiphan N, Link M, Josephson ME, Buxton AE.
    Heart Rhythm; 2014 Jul; 11(7):1109-16. PubMed ID: 24837348
    [Abstract] [Full Text] [Related]

  • 3. Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies.
    Arnaldo FJ, Anatoliotakis N, Palacio C, Nabert DR, Hsu SS.
    Heart Lung; 2009 Jul; 38(1):10-6. PubMed ID: 19150526
    [Abstract] [Full Text] [Related]

  • 4. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
    Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, Arfanakis DA, Vardas PE.
    Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
    [Abstract] [Full Text] [Related]

  • 5. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs.
    Mordi I, Jhund PS, Gardner RS, Payne J, Carrick D, Berry C, Tzemos N.
    JACC Cardiovasc Imaging; 2014 Jun; 7(6):561-9. PubMed ID: 24813968
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Eldadah Z, Ellenbogen KA, Dickfeld T, Spragg DD, Marine JE, Guallar E, Tomaselli GF.
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG.
    Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
    [Abstract] [Full Text] [Related]

  • 10. Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers.
    Scott PA, Townsend PA, Ng LL, Zeb M, Harris S, Roderick PJ, Curzen NP, Morgan JM.
    Europace; 2011 Oct; 13(10):1419-27. PubMed ID: 21784745
    [Abstract] [Full Text] [Related]

  • 11. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
    Yu H, Oswald H, Gardiwal A, Lissel C, Klein G.
    Am J Cardiol; 2007 Aug 15; 100(4):635-9. PubMed ID: 17697820
    [Abstract] [Full Text] [Related]

  • 12. Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients.
    Bae MH, Cho Y, Hwang J, Park HS, Han S, Lee YS, Cho HJ, Jung BC, Lee CH, Hyun DW, Park JS, Ahn J, Kim KH, Shin DG.
    J Korean Med Sci; 2020 Mar 09; 35(9):e49. PubMed ID: 32141247
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose-response meta-analysis.
    Prameswari HS, Putra ICS, Kamarullah W, Pranata R, Iqbal M, Karwiky G, Pramudyo M, Kusumawardhani NY, Achmad C, Martha JW, Akbar MR.
    Open Heart; 2023 Mar 09; 10(1):. PubMed ID: 36927867
    [Abstract] [Full Text] [Related]

  • 16. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA, O'Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, Butler J, Lam CSP, Ponikowski P, Emdin M, Patel MJ, Pieske B, Roessig L, Hernandez AF, Armstrong PW.
    JACC Heart Fail; 2020 Nov 09; 8(11):931-939. PubMed ID: 33039447
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
    Zhang Y, Kennedy R, Blasco-Colmenares E, Butcher B, Norgard S, Eldadah Z, Dickfeld T, Ellenbogen KA, Marine JE, Guallar E, Tomaselli GF, Cheng A.
    Heart Rhythm; 2014 Aug 09; 11(8):1377-83. PubMed ID: 24793459
    [Abstract] [Full Text] [Related]

  • 20. Baroreflex sensitivity assessed with the sequence method is associated with ventricular arrhythmias in patients implanted with a defibrillator for the primary prevention of sudden cardiac death.
    Garcia R, Degand B, Fraty M, Le Marcis V, Bidegain N, Laude D, Tavernier M, Le Gal F, Hadjadj S, Saulnier PJ, Ragot S.
    Arch Cardiovasc Dis; 2019 Apr 09; 112(4):270-277. PubMed ID: 30670362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.